IR@PKUHSC  > 北京大学第二临床医学院  > 眼科
学科主题临床医学
Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population
Qi, Hui-Jun; Li, Xiao-Xin; Tao, Yong
关键词Bevacizumab Idiopathic Choroidal Neovascularization Chinese Population
刊名CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
2010-08-01
DOI10.3129/i10-019
45期:4页:381-385
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Ophthalmology
研究领域[WOS]Ophthalmology
关键词[WOS]MACULAR DEGENERATION ; TRANSPUPILLARY THERMOTHERAPY ; PHOTODYNAMIC THERAPY ; ANGIOID STREAKS ; YOUNG-PATIENTS ; CASE SERIES ; AGE ; AVASTIN ; VERTEPORFIN
英文摘要

Objective: To assess the long-term visual and anatomical outcomes and safety of intravitreal injection of bevacizumab for idiopathic choroidal neovascularization (ICNV) in Chinese patients.

Design: Retrospective interventional case series.

Participants: Seventy-seven eyes of 77 patients with ICNV.

Methods: Patients were given intravitreal injection of bevacizumab (1.25 mg/0.05 mL) for ICNV between March 2006 and May 2008. Main outcome measures were changes in best-corrected visual acuity (BCVA), central foveal thickness, which was measured by optical coherence tomography, and fluorescein angiography findings.

Results: Mean follow-up was 14.3 (SD 2.4, range 10 similar to 20) months. Mean BCVA improved from 0.66 (SD 0.36) logMAR at baseline to 0.25 (SD 0.28) logMAR at final follow-up (p < 0.001). Sixty-one patients (79%) gained BCVA of >= 2 Snellen lines, and 1 eye (1%) lost BCVA of >= 2 Snellen lines. Mean central foveal thickness decreased from 365 (SD 124) mu m at baseline to 211 (SD 94) pm at final visit (p < 0.001). Sixty-two eyes (81%) needed reinjection. Both BCVA improvement and the change in central foveal thickness between the 1- time injection group and the multi-injections group were not statistically significant (p = 0.45 and p = 0.19, respectively). No significant ocular or systemic adverse effects were observed.

Conclusions: The long-term results suggest an encouraging efficacy and safety of intravitreal bevacizumab for ICNV in Chinese patients.

语种英语
WOS记录号WOS:000281463000011
项目编号2006BAI02B05 ; 30901639
资助机构Key Project Grant in the National Science &amp ; Technology Pillar Program ; National Natural Science Foundation of China (Beijing, China)
引用统计
被引频次:11[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51438
专题北京大学第二临床医学院_眼科
作者单位Peking Univ, Peoples Hosp, Dept Ophthalmol, Beijing 100044, Peoples R China
推荐引用方式
GB/T 7714
Qi, Hui-Jun,Li, Xiao-Xin,Tao, Yong. Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population[J]. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE,2010,45(4):381-385.
APA Qi, Hui-Jun,Li, Xiao-Xin,&Tao, Yong.(2010).Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population.CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE,45(4),381-385.
MLA Qi, Hui-Jun,et al."Outcome of intravitreal bevacizumab for idiopathic choroidal neovascularization in a Chinese population".CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE 45.4(2010):381-385.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Qi, Hui-Jun]的文章
[Li, Xiao-Xin]的文章
[Tao, Yong]的文章
百度学术
百度学术中相似的文章
[Qi, Hui-Jun]的文章
[Li, Xiao-Xin]的文章
[Tao, Yong]的文章
必应学术
必应学术中相似的文章
[Qi, Hui-Jun]的文章
[Li, Xiao-Xin]的文章
[Tao, Yong]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。